1. Introduction
===============

Porcine circovirus type 2 (PCV2) is one of the most widespread viruses that cause economically relevant infections in swine. After its first identification in the late 1990s, PCV2 is linked with a variety of disease manifestations, such as postweaning multi-systemic wasting syndrome (PMWS), porcine dermatitis and nephropathy syndrome (PDNS), porcine respiratory disease complex (PRDC), and reproductive failure ([@vez026-B1]; [@vez026-B48]; [@vez026-B22]; [@vez026-B33]). All these diseases are collectively termed porcine circovirus-associated diseases (PCVAD) ([@vez026-B43]). Retrospective serological studies performed on archived samples confirmed PCV2 infections from 1962 in Germany, 1969 in Belgium, 1970 in the UK, 1973 in Ireland, and 1985 in Spain and Canada ([@vez026-B34]; [@vez026-B68]; [@vez026-B57]; [@vez026-B47]; [@vez026-B16]; [@vez026-B21]). This demonstrated that PCV2 circulated years prior to its identification.

PCV2 belongs to the *Circovirus* genus of the family *Circoviridae*. It is an icosahedral and non-enveloped DNA virus, with a diameter of only 17 nm. The single-stranded circular PCV2 genome is comprised of 1,766--8 nucleotides (nt) ([@vez026-B17]). It contains two major open reading frames (ORFs): ORF1 encodes two replication-associated proteins (rep and rep′), which is essential for the multiplication of the PCV2 genome but absent in the assembled virion; ORF2 encodes a viral capsid protein (cap), which is the only structural protein. The capsid protein determines the antigenicity and virulence of PCV2 ([@vez026-B18]; [@vez026-B40]; [@vez026-B30]; [@vez026-B53]). Mutation of one or two amino acids in the cap may affect the virulence and pathogenicity of PCV2 ([@vez026-B20]; [@vez026-B52]). In addition, ORF2 alone can serve as a phylogenetic and epidemiologic marker for comparative analysis of PCV2 ([@vez026-B41]).

Based on phylogenetic analysis of PCV2 genomic or ORF2 sequences, PCV2 can be divided into six subtypes (PCV2a--f). PCV2a and PCV2b have been documented worldwide ([@vez026-B60]). PCV2a was the most prevalent genotype until approximately 2003 while PCV2b became the predominant one after 2004 ([@vez026-B61]). This indicates an obvious genotype shift from PCV2a to PCV2b, which was described in several countries ([@vez026-B4]; [@vez026-B5]; [@vez026-B8]; [@vez026-B64]; [@vez026-B71]; [@vez026-B6]; [@vez026-B61]). This shift on genotype prevalence coincided with the advent of the most severe outbreaks of PCVAD. However, under experimental conditions, the virulence of PCV2a and PCV2b does not differ significantly ([@vez026-B42]; [@vez026-B50]). PCV2c was initially detected in archived swine serum samples in Denmark, and has recently been found in a feral pig in Brazil ([@vez026-B8]; [@vez026-B12]). However, this genotype is likely of minor importance. The origin of PCV2d strains can be traced back to 1998 in Switzerland and is now widespread in many countries, suggesting a genotype shift from PCV2b to PCV2d ([@vez026-B69]; [@vez026-B72]; [@vez026-B27]; [@vez026-B45]; [@vez026-B63]). PCV2d is divided into two subclades, PCV2d-1 and PCV2d-2 ([@vez026-B72]). The majority of PCV2d-1 strains were circulating during 1999--2011 while PCV2d-2 was first identified in 2006, indicating that PCV2d-1 is a possible ancestor of PCV2d-2 ([@vez026-B72]). The fifth genotype, PCV2e, was first discovered in Mexican pigs and then in the USA in a retrospective study, with the earliest sequence dating back to 2006 ([@vez026-B19]; [@vez026-B7]). The last genotype, PCV2f, was first identified in China and is also present in Croatia, India, and Indonesia ([@vez026-B2]).

In Belgium, the presence of PCV2 was demonstrated in 1969 based on a retrospective serological analysis of PCV2 antibodies in domestic and feral pig populations ([@vez026-B57]). Large PMWS outbreaks have never been described in Belgium ([@vez026-B28]; [@vez026-B36]). It is thought that the use of Piétrain boars for the production of hybrid fattening pigs forms the basis of this low susceptibility. Recent work has demonstrated a more efficient uptake and disintegration of PCV2 by monocytes from purebred Piétrain than those from purebred Landrace and Large White, which may in part explain this better resistance ([@vez026-B70]). Until now, only four Belgian strains were isolated from PMWS-affected piglets: strains 1206 and VC2002-K39 were identified as PCV2b, strain VC2002-K2 as PCV2d-1 (originally identified as PCV2b based on the old classification system), and strain 4D4 as a recombinant strain of VC2002-K2 and VC2002-K39 ([@vez026-B36], [@vez026-B37]; [@vez026-B30], [@vez026-B29]; [@vez026-B54]; [@vez026-B72]). Despite continuous reports of newly emerging strains and global genotype shifts, there was little information available regarding the molecular epidemiology and evolution of PCV2 in Belgium. The objectives of this study were to examine the prevalence and genetic evolution of PCV2 in Belgium from 2009 till 2018, and to find the driving force behind PCV2 evolution by analyzing the amino acid differences.

2. Materials and methods
========================

2.1 Sample collection
---------------------

A total of 319 samples (lungs, kidneys, spleen, lymph nodes, serum, or a mix of organs) were collected from unthrifty pigs with clinical signs of PCVAD in different regions of Belgium from 2009 to 2018. These samples were submitted for diagnostic analysis to the Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University. A piece of the organ samples was homogenized for virus titration and DNA extraction, and the rest of the samples were stored at −70 °C.

2.2 Virus isolation and titration
---------------------------------

Twenty per cent (w/v) suspensions of each tissue sample or pools were made in cold PBS. Afterward, the PCV2 titers were determined by virus titration on PK-15 cells as described elsewhere ([@vez026-B55]). The virus titers were expressed as log~10~TCID~50~/g of tissue (TCID~50~ = tissue culture infectious dose with 50% endpoint). Samples were categorized into three groups with high (≥4.5 log~10~TCID~50~/g), medium (3--4.5 log~10~TCID~50~/g), and low (≤3 log~10~TCID~50~/g) virus titers according to previously defined criteria ([@vez026-B56]). The detection limit of this technique was 10^1.7^ TCID~50~/g tissue ([@vez026-B51]).

2.3 DNA extraction, PCR, and sequencing
---------------------------------------

Total DNA was extracted from tissue homogenates or serum using QIAamp Cador Pathogen mini kit (Qiagen) following the manufacturer's instructions. The viral DNA extracted from PCV2 strain 1121 virus stock and double distilled water were used as positive and negative controls during PCR analysis, respectively. To amplify the ORF2 gene, a conventional PCR assay was performed using two primer pairs (ORF2-fw: 5′-gcgcacttcttttcgttttcag-3′, ORF2-rev: 5′-gaatgcggccgcttatcacttcgtaatggtttttattattca-3′; pgPCV2-fw: 5′-ggctgtggcctttgktac-3′, pgPCV2-rev: 5′-tgtrgaccacgtaggcctcg-3′) ([@vez026-B30]; [@vez026-B70]). The PCR reaction (25 µl) contained 5 µl of 5 × PCR buffer, 0.2 µl of 100 mM dNTPs, 1 µl of 10 µM primers each, 5 µl of DNA template, 0.5 µl of Herculase II fusion DNA polymerase, and 12.3 µl water. The thermal cycling programme for the PCR reaction was 94 °C for 2 min, then 30 cycles of 94 °C for 15 s, 54 °C for 30 s, and 68 °C for 1 min (ORF2-fw/rev) or for 2 min (pgPCV2-fw/rev), followed by 68 °C for 10 min. The amplification products were examined by agarose gel electrophoresis and were visualized by ethidium bromide staining and UV light. The amplicons were sent to GATC (Constance, Germany) for Sanger sequencing. The sequences of the DNA fragments were then assembled using EditSeq programme of the DNASTAR version 7.0 (DNASTAR Inc., Madison, WI, USA).

2.4 Bioinformatics analysis
---------------------------

Forty-three ORF2 nucleotide sequences obtained in this study and twenty-nine published PCV2 ORF2 sequences available in GenBank ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}) were included in the phylogenetic analysis. All sequences were aligned using the Clustal W method of the MegAlign programme of the DNASTAR version 7.0. Nucleotide and amino acid sequence similarities were analysed based on the aligned dataset. A phylogenetic tree was constructed using the neighbour-joining method in MEGA 7 software ([@vez026-B26]). Reliability of the neighbour-joining tree was calculated using 1,000 bootstrap replicates. Sequences obtained were deposited in GenBank.

2.5 Selection pressure analysis
-------------------------------

An analysis of selection pressure on the cap protein was evaluated using different methods in the Datamonkey (<http://www.datamonkey.org>), based on the ratios between non-synonymous and synonymous substitution rates (dN-dS) ([@vez026-B44]). Pervasive and episodic diversifying/purifying selection was estimated using single-likelihood ancestor counting (SLAC), fixed effects likelihood (FEL), mixed effects model of evolution (MEME), and fast unconstrained Bayesian approximation (FUBAR) ([@vez026-B44]; [@vez026-B38], [@vez026-B39]). The positive signals were accepted when the *P*-value was below 0.1 in SLAC, FEL, and MEME and when the posterior probability (Post. Pr.) was above 0.9 in FUBAR. Sites were assumed to be under positive selection pressure when the positive signals were detected by at least two methods.

2.6 Three-dimensional (3D) mapping of amino acids in the PCV2 cap protein
-------------------------------------------------------------------------

The accurate 3D structures of PCV2 cap protein of different genotypes were predicted using iterative threading assembly refinement (I-TASSER) server (<https://zhanglab.ccmb.med.umich.edu/I-TASSER/>) based on the sequence of a PCV2a strain (Fh17; GenBank no. [AY322004](AY322004)), a PCV2b strain (1206; GenBank no. [EF990644](EF990644)), and a PCV2d strain (K2; GenBank no. [EF990645](EF990645)) ([@vez026-B74]; [@vez026-B49]; [@vez026-B73]). The structures of cap protein were displayed with PyMOL software (South San Francisco, CA, USA).

3. Results
==========

3.1 Percentage of infectious PCV2-positive cases in Belgium from 2009 till 2018
-------------------------------------------------------------------------------

The total number of collected cases and virus isolation positive cases of each year are shown in [Table 1](#vez026-T1){ref-type="table"}. Of the 319 clinical samples, 50 samples (15.7%) were positive for PCV2 by virus titration. The total samples were then categorized by virus titer (log~10~TCID~50~/g) ([@vez026-B56]). Eight per cent of the samples (25/319) contained large amounts of infectious PCV2 (≥4.5 log~10~TCID~50~/g), 1 per cent of the samples (3/319) contained moderate amounts of infectious PCV2 (3--4.5 log~10~TCID~50~/g), 7 per cent of the samples (22/319) contained low amounts of infectious PCV2 (≤3 log~10~TCID~50~/g), and 84 per cent of the samples (269/319) were negative for PCV2 isolation.

###### 

Number of total collected samples, PCV2 isolation-positive cases, PCR-examined cases, and PCV2 genotypes identified each year in 319 samples collected from 2009 to 2018 in Belgium.

  Year    Total collected   Virus isolation positive (%)   PCR examined   PCV2a   PCV2b   PCV2d   
  ------- ----------------- ------------------------------ -------------- ------- ------- ------- ---
  2009    141               26 (18.4%)                     16/26          3       12      1       0
  2010    104               12 (11.5%)                     12/12          0       7       5       0
  2011    29                4 (13.8%)                      4/4            0       4       0       0
  2012    18                4 (22.2%)                      4/4            0       4       0       0
  2013    7                 4 (57.1%)                      4/4            0       4       0       0
  2014    3                 0                              0              0       0       0       0
  2015    7                 0                              0              0       0       0       0
  2016    1                 0                              0              0       0       0       0
  2017    3                 0                              0              0       0       0       0
  2018    6                 0                              3              0       0       0       3
  Total   319               50 (15.7%)                     43             3       31      6       3

3.2 Sequencing of PCV2 ORF2
---------------------------

A total of forty-three samples were subjected to DNA extraction and PCR amplification of the ORF2 gene. The distribution of these PCR-examined samples in each year is shown in [Table 1](#vez026-T1){ref-type="table"}. Sixteen PCV2 isolates from 2009 were randomly selected for further PCR analysis from the twenty-six PCV2-titration positive cases due to a relatively large sample size; all PCV2 isolates from 2010 till 2017 (twelve isolates in 2010, four isolates in 2009, four isolates in 2010, four isolates in 2013 and zero isolate in 2014--7) were analyzed by PCR; three out of six serum samples collected in 2018 that were PCR positive were further sequenced. The detailed information of these PCR-examined samples is shown in [Table 2](#vez026-T2){ref-type="table"}, including the code, year of isolation, tissue origin, PCV2 titer, and GenBank accession number. The complete ORF2 sequences were 702 or 705 base pairs (bp) in length.

###### 

Information on PCV2 PCR-positive isolates collected in Belgium from 2009 to 2018.

  No.   Isolates (cases)   Collection year   Sample                PCV2 titers (log~10~TCID~50~/g)               Accession No.   Genotype
  ----- ------------------ ----------------- --------------------- --------------------------------------------- --------------- ----------
  1     09V003             2009              Mixed organs          4.7                                           MK005834        2b
  2     09V005             2009              Lung                  2.0                                           MK005831        2a
  3     09V019             2009              Spleen                4.5                                           MK005835        2b
  4     09v026             2009              Lymph node            ≥5.5                                          MK005832        2a
  5     09V042             2009              Lung + lymph node     ≥5.5                                          MK005836        2b
  6     09V089             2009              Organs foetus         Positive[^a^](#tblfn1){ref-type="table-fn"}   MK005833        2a
  7     09V117-1           2009              Lung                  4.3                                           MK005837        2b
  8     09V117-2           2009              Lung                  ≥5.5                                          MK005838        2b
  9     09V118             2009              Spleen                4.7                                           MK005839        2b
  10    09V141             2009              Lung                  5.0                                           MK005840        2b
  11    09V153             2009              Lymph node            ≥5.5                                          MK005841        2b
  12    09V178             2009              Lymph node            3.0                                           MK005842        2b
  13    09V257             2009              Spleen                2.0                                           MK005843        2b
  14    09V408             2009              Lung                  3.2                                           MK005844        2b
  15    09V410             2009              Kidney                2.0                                           MK005845        2b
  16    09V448             2009              Lymph node            5.5                                           MK005865        2d-1
  17    10V005             2010              Lymph node            4.7                                           MK005846        2b
  18    10V008             2010              Lung                  2.5                                           MK005847        2b
  19    10V009             2010              Spleen + lymph node   4.7                                           MK005866        2d-1
  20    10V059             2010              Lymph node            2.5                                           MK005848        2b
  21    10V139             2010              Lung                  3.0                                           MK005849        2b
  22    10V147             2010              Lymph node            4.5                                           MK005850        2b
  23    10V149             2010              Lung + lymph node     5.5                                           MK005867        2d-1
  24    10V183             2010              Lymph node + heart    2.0                                           MK005851        2b
  25    10V232             2010              Lymph node            ≥5.5                                          MK005852        2b
  26    10V513             2010              Lung                  2.5                                           MK005868        2d-1
  27    10V532             2010              Spleen + lung         2.0                                           MK005869        2d-1
  28    10V542             2010              Lymph node            2.0                                           MK005870        2d-1
  29    11V012             2011              Lymph Node            5.3                                           MK005853        2b
  30    11V152             2011              Spleen                1.7                                           MK005854        2b
  31    11V300             2011              Lung                  ≥5.5                                          MK005855        2b
  32    11V519             2011              Lung                  Positive[^a^](#tblfn1){ref-type="table-fn"}   MK005856        2b
  33    12V001             2012              Organs foetus         2.8                                           MK005857        2b
  34    12V042-1           2012              Mixed organs          4.5                                           MK005858        2b
  35    12V042-2           2012              Mixed organs          4.5                                           MK005859        2b
  36    12V042-3           2012              Mixed organs          4.5                                           MK005860        2b
  37    13V067             2013              Lung                  ≥5.5                                          MK005861        2b
  38    13V068             2013              Spleen                5.0                                           MK005862        2b
  39    13V069             2013              Lymph node            ≥5.5                                          MK005863        2b
  40    13V071             2013              Spleen                5.0                                           MK005864        2b
  41    18v047             2018              Serum                 Negative                                      MH287045        2d-2
  42    18v126             2018              Serum                 Negative                                      MK005871        2d-2
  43    18v152             2018              Serum                 Negative                                      MK005872        2d-2

Positive means that the sample was positive for virus isolation, but the corresponding virus titer was not recorded.

3.3 Phylogenetic and homology analyses of PCV2 ORF2 sequences
-------------------------------------------------------------

Genetic and phylogenetic analyses were performed using ORF2 sequences of forty-three Belgian PCV2 isolates and twenty-nine reference sequences deposited in GenBank by neighbour-joining method. The phylogenetic tree showed that the forty-three PCV2 sequences obtained could be classified into three distinct genotypes ([Fig. 1](#vez026-F1){ref-type="fig"}). Three of the forty-three (7%) PCV2 isolates belonged to genotype 2a, thirty-one of the forty-three (72%) isolates to genotype 2b, and nine of the forty-three (21%) isolates to genotype 2d. PCV2c, PCV2e, and PCV2f genotypes were not detected in the sample set.

![Phylogenetic analysis of PCV2 isolates based on ORF2 sequences obtained in this study (▲) together with the reference sequences from GenBank. The neighbour-joining tree was constructed by molecular evolutionary genetics analysis (MEGA) software version 7.0. The PCV1 and PCV3 sequences provided an outgroup to root the tree.](vez026f1){#vez026-F1}

The genotype distribution of the forty-three Belgian PCV2 isolates from 2009 till 2018 is listed in [Table 1](#vez026-T1){ref-type="table"}. All three samples of PCV2a genotype were collected in 2009. Two of them clustered with an isolate in Canada (GenBank no. [AF109398](AF109398)), while one of them clustered with an isolate from France in 2003 (GenBank no. [AY322004](AY322004)). PCV2b was the most common genotype found from 2009 to 2013, with relatively limited genetic diversity. PCV2d formed an independent cluster which was further subdivided into two separate subclades: PCV2d-1 and PCV2d-2. Interestingly, PCV2d-1 isolates were found in 2009 (1/6) and in 2010 (5/6), while in 2018 all PCV2d sequences clustered in the PCV2d-2 clade (3/3). Furthermore, one strain 10V009 from the PCV2d-1 clade clustered with the VC2002-K2, the first isolated Belgian PCV2d-1 strain ([@vez026-B36]; [@vez026-B53]; [@vez026-B72]).

The length of the ORF2 of PCV2a and PCV2b was 702 bp, while that of PCV2d was 705 bp resulting in an additional amino acid, lysine, at the 3′-terminus of the capsid protein. Pairwise-sequence comparisons revealed that the complete ORF2 sequences of forty-three PCV2 isolates shared 89.7--100 per cent nucleotide sequence and 88.5--100 per cent amino acid sequence identities. For each genotype, the homology of nucleotide and amino acid sequences were as follows: for the PCV2a isolates (*n* = 3): 94.9--99.9 per cent and 95.4--100 per cent; for the PCV2b isolates (*n* = 31): 95.2--100 per cent and 94--100 per cent, and for the PCV2d isolates (*n* = 9): 97.7--100 per cent and 97.0--100 per cent ([Table 3](#vez026-T3){ref-type="table"}). The PCV2d sequences exhibited the lowest variability among the three Belgian PCV2 genotypes. Despite this highest homology, the Belgian PCV2d genotype could be separated into two subtypes. The ORF2 gene of 6 PCV2d-1 isolates demonstrated 97.9--99.4 per cent nucleotide sequence and 97.0--99.1 per cent amino acid sequence identities whereas that of three PCV2d-2 sequences had 97.7--100 per cent and 97.0--100 per cent identities.

###### 

Per cent of nucleotide and amino acid sequence similarity of ORF2 among reference strains and PCV2 isolates in our study by pairwise comparison.

                                              Nucleotide (nt) and amino acid (aa) identities of strains (%)                                                                                 
  ------------------------------------- ----- --------------------------------------------------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------
  Type C (AF109398) (PCV2a)             nt    100                                                             95.2--97.5   93.5         91.9--94     92.3         91.2--92.3   92.1         92.1
  aa                                    100   93.1--96.2                                                      91.9         88.8--93.8   89.4         88.1--89.4   88.8         88.8         
  Isolates in our study (PCV2a)         nt    --                                                              94.9--99.9   92.6--93.3   91.5--95.2   90.0--93.7   89.7--94.2   90.2--93.4   90.0--93.6
  aa                                    --    95.7--100                                                       90.6--91.9   89.3--94.9   88.9--90.2   87.2--90.6   87.6--89.7   87.6--90.2   
  1206 (EF990644) (PCV2b)               nt    --                                                              --           100          98.3--99.6   93.6         93.4--94.6   94.3         94.2--94.3
  aa                                    --    --                                                              100          95.3--99.6   93.2         93.2--94.4   93.6         93.6         
  Isolates in our study (PCV2b)         nt    --                                                              --           --           95.2--100    92.3--94.7   92.6--95.4   93.2--95.4   93.0--95.4
  aa                                    --    --                                                              --           94.0--100    91.5--94.9   91.0--96.2   91.9--95.3   91.9--95.3   
  VC2002-K2 (EF990645) (PCV2d-1)        nt    --                                                              --           --           --           100          97.9--99.3   98           97.9
  aa                                    --    --                                                              --           --           100          97.4--99.1   98.3         97.9--98.3   
  Isolates in our study (PCV2d-1)       nt    --                                                              --           --           --           --           97.9--99.4   97.9--98.4   97.7--98.3
  aa                                    --    --                                                              --           --           --           97.0--99.1   97.4--99.1   97.0--100    
  BDH (HM038017) (PCV2d-2)              nt    --                                                              --           --           --           --           --           100          99.9
  aa                                    --    --                                                              --           --           --           --           100          99.6--100    
  PCR isolates in our study (PCV2d-2)   nt    --                                                              --           --           --           --           --           --           97.7--100
  aa                                    --    --                                                              --           --           --           --           --           97.0--100    

3.4 Selection pressure analysis
-------------------------------

Selection pressure on the capsid protein of Belgian PCV2 isolates was estimated. In the difference between non-synonymous and synonymous substitution rates (dN-dS), the cap gene was negative (−1.575), indicating that the capsid of Belgian PCV2 had evolved under purifying selection. This is in accordance with previous studies where purifying selection was identified in the cap gene ([@vez026-B41]; [@vez026-B72]). However, three codons (positions 59, 131, and 191) were identified under positive selection through the MEME (*P* \< 0.1) and FUBAR approaches (Post. Pr. \> 0.9) ([Table 4](#vez026-T4){ref-type="table"}). Position 59 is a critical amino acid that is part of the neutralizing epitope ([@vez026-B20]); position 131 is important for determining neutralization activity ([@vez026-B52]); and the mutation at position 191 may affect the growth ability of PCV2 both *in vitro* and *in vivo* ([@vez026-B10]).

###### 

Selection pressure analysis of cap protein of PCV2 using SLAC, FEL, MEME, and FUBAR methods.

  Codon   SLAC   FEL          MEME     FUBAR                                    
  ------- ------ ------------ -------- ----------- -------- ---------- -------- -----------
  59      3.95   0.348        −0.272   0.898       184.84   **0.00**   14.118   **0.913**
  131     6.22   0.151        2.393    0.159       3.47     **0.09**   6.623    **0.973**
  191     6.74   **0.0869**   4.695    **0.098**   7.04     **0.02**   5.287    **0.984**

Codon with *P*-value \< 0.1 in SLAC, FEL, and MEME methods, or with Post. Pr. ≥ 0.9 in FUBAR method (showed in bold), was considered under positive selection. Condon: positively selected sites (AA), *β*^+^: the MLE of the unconstrained *β* non-synonymous rate, and Post. Pr.: posterior probability.

3.5 Amino acid analysis of PCV2 cap sequences
---------------------------------------------

The amino acid alignment of the capsid protein encoded by the ORF2 gene was further conducted for the forty-three PCV2 strains in this study ([Supplementary Fig. S1](#sup1){ref-type="supplementary-material"}). Amino acid comparisons among the forty-three PCV2 isolates and twenty-one reference strains revealed that a greater diversity was found in three major regions (53--91, 121--136, and 169--217) and at three major positions (151, 232, and 234). Moreover, certain amino acids only appear in strains of one but not the other two genotypes. For instance, ten amino acid residues (75N/K, 76L, 86T, 88K, 89I, 91I, 123I/V, 136Q, 190S/T, and 232N/K, indicated in red) were only found in clusters of PCV2a isolates; fifteen (11K/R, 29F/L, 82K/P, 85H/G, 89L/R, 112P/T, 141S/Y, 169A/S, 188H/Q, 190A, 206V, 210D/G/E, 215G/I/V, 217L/M, and 222T/R, indicated in orange) in PCV2b isolates, and twelve (10G/R, 53I, 59A/K/R, 68N, 130I/V, 134N, 169W/R/G, 188P/Q, 200P/T, 207H/Y, 215I, and 216A/T, indicated in green) in the clusters of PCV2d ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). Among these variable amino acids, some mutations were limited to a few strains, such as 11K/R among PCV2b isolates, with K present in one out of thirty-one PCV2b isolates and R in the remaining thirty strains. These mutations seldom reflect the whole picture of PCV2 genotypic evolution, and thus are of little importance.

Other mutations were present in all or at least the majority of the strains of the genotype, such as 57V/I among PCV2b isolates, with V present in two out of thirty-one PCV2b isolates and one in the other twenty-nine strains. These mutations may represent the general evolutionary trace of that genotype, and is thereby of great importance. Such mutations were selected and presented in [Table 5](#vez026-T5){ref-type="table"}. Amino acids at these important mutation sites were mapped on the corresponding 3D structure of the cap protein of PCV2a (strain Fh17), PCV2b (strain 1206), and PCV2d (strain K2) ([Fig. 2](#vez026-F2){ref-type="fig"}). Different colour codes were used for different amino acid sites, and the same colour was used for the same amino acid site across the three different genotypes. On the inner side of the cap protein where the cap protein interacts with the viral genome, three mutations at positions 53 (F-F-I), 121 (S-S-T), and 215 (V-V-I) were found on the β-sheet structure across the three genotypes (PCV2a--PCV2b--PCV2d). These mutations are conserved and less likely to induce any changes, since F, I, and V belong to the hydrophobic amino acids, and S and T to the polar amino acids. Because the amino acids of the inner part of the cap protein that interact with the viral genome are conserved, it became clear that the inner β-sheets are essential in the PCV2 morphogenesis and stability of the structure. Interestingly, most of the amino acid mutations were found on the outside of the cap protein where the cap protein interacts with the environment. On the upper part of the cap protein, mutations were found in amino acids at positions 59, 206, and 63 that were very close to each other and formed a large surface area (A/K/S for PCV2a, R/I/R for PCV2b, and A/K/R for PCV2d). It is obvious that this area became more basic with the evolution from PCV2a to PCV2b and PCV2d, due to the formation of a cluster of basic polar amino acids (K + R). A single amino acid at position 169 (S-S-R) followed this trend as well. This indicated that this area of the PCV2 capsid was evolving toward more positive charges which may lead to a more efficient binding to the negatively charged glycosaminoglycan (GAG) receptors. Another large surface area where mutations were found was formed by amino acids at positions 57, 68, and 134, which is V/A/T for PCV2a, I/A/T for PCV2b, and V/N/N for PCV2d. Compared with PCV2a and PCV2b, this area of PCV2d increased its polarity by adding a second polar amino acid (NN) instead of a non-polar amino acid (A, I, or V). In this way, a better environment is created for receptor binding by hydrogen bonds. Similarly, a single mutation of the amino acid at position 131 (I-T-T) also shifted from a hydrophobic amino acid (I) to a polar one (T), which fitted in this hypothesis as well. Together, this suggested that, with mutations of amino acids at the upper part of the cap protein, PCV2 has evolved for a more efficient binding with GAGs. On the lower part of the cap protein, there were three large surface areas which were formed by groups of mutated amino acids among three genotypes. The first one (V/D/S for PCV2a, I/N/A for PCV2b, and L/N/T for PCV2d) was formed by amino acids at positions 80, 77, and 190; the second one (V/S/I for PCV2a, L/S/V for PCV2b, and L/T/V for PCV2d) was formed by amino acids at positions 80, 90, and 91; and the last one (T/K/I for PCV2a, S/P/R for PCV2b, and S/P/L for PCV2d) was formed by amino acids at positions 86, 88, and 89. Mutations in the former two areas were generally conserved, since the mutated amino acids were replaced by ones with similar biochemical properties; mutations in the last area resulted in a loss of the basic positively charged polar amino acid. This means that there were less changes in the lower part of the capsid protein. On the 'tail' part of the cap protein, an amino acid at position 232 changed from a basic polar K for PCV2a to a polar neutral N for both PCV2b/d. For PCV2d, there was an extra basic polar amino acid K at position 234, while this amino acid K at position 234 was absent for PCV2a/b. Moreover, the surface of the basic polar amino acid K at position 234 was very close to that of the polar amino acid N at position 232 for PCV2d. It was inferred that the polar amino acid N at position 232 could extend further from the capsid surface, thus projecting the neighbouring positively charged K to the outer environment to search for/enhance the initial, non-specific interaction of the virus with negatively charged heparan/chondroitin sulphate on the cell membrane during PCV2 infection.

###### 

Genotype-specific amino acid residues in the cap protein of forty-three Belgian PCV2 isolates (PCV2a: three isolates; PCV2b: thirty-one isolates; PCV2d-1: six isolates; and PCV2d-2: three PCR isolates) and twenty-one reference strains (PCV2a: eight strains; PCV2b: seven strains; PCV2d-1: two strains; and PCV2d-2: four strains).

  Position   PCV2a   PCV2b      PCV2d-1     PCV2d-2                              
  ---------- ------- ---------- ----------- --------- ---------- ------- ------- -------
  53         F       F          F           F         I          I       I       I
  57         V       V          2V/29I      3V/4I     V          V       V       V
  59         R       2R/6A      R           R         1A/1R/4K   A       K       K
  63         1S/2T   1S/3R/4T   1T/9R/21K   3K/4R     R          R       R       R
  68         A       A          A           A         N          N       N       N
  77         D       1N/7D      1D/30N      N         N          N       N       N
  80         V       1L/7V      1V/30L      L         L          L       L       L
  86         T       T          S           S         S          S       S       S
  88         K       K          P           P         P          P       P       P
  89         I       I          1L/30R      R         L          L       L       L
  90         S       S          1T/30S      S         T          T       T       T
  91         I       1V/7I      V           V         V          V       V       V
  121        S       3S/5T      1T/30S      S         T          T       T       T
  131        1I/2P   1I/3T/4P   12P/19T     T         T          T       T       T
  134        T       1P/7T      T           T         N          N       N       N
  151        1P/2T   1T/7P      T           1P/6T     1T/5P      P       T       T
  169        1S/2G   S          1A/30S      S         1W/5R      R       1R/2G   2R/2G
  190        1S/2T   S          A           A         T          T       T       T
  206        K       K          1V/30I      I         I          1K/1I   I       I
  210        D       D          1D/2G/28E   E         2D/4E      D       D       D
  215        V       V          1G/1I/29V   V         I          I       I       I
  232        K       1N/6K      N           N         N          N       N       N
  234        --      --         --          --        K          K       K       K

PCV2a reference sequences: AY556474, AF109398, AY180396, AF201308, AY322004, AJ293868, AF055392, AB072301; PCV2b reference sequences: EF990646, EF990644, AY916791, AY691169, AY484407, AY424405, AY321984; PCV2d reference sequences: EF990645, AB462384 (PCV2d-1); KJ187306, JX535296, JX519293, HM038017. --, Dashes indicate amino acid residues at this position are absent among these PCV2 genotypes.

One reference strain PCV2a-AF109398-Canada1998 has only a partial cap sequence (positon 1-168) deposited on GenBank.

![Three-dimensional mapping of critical amino acids presented in [Table 5](#vez026-T5){ref-type="table"} on capsid of PCV2a, PCV2b, and PCV2d. The 3D structures of capsid were generated using I-TASSER server and displayed with PyMOL.](vez026f2){#vez026-F2}

In conclusion, the amino acid motifs were multi-variate in the cap sequences of these forty-three Belgian PCV2 isolates. From an evolutionary point of view, most amino acid mutations were found on the outer surface of the cap protein, with the upper and tail parts of the cap protein consisting of more basic amino acid clusters and the lower part being more conserved but somewhat less basic; the amino acids at the inner part were conserved to interact with the viral genome and maintain the stability of the PCV2 virion.

4. Discussion
=============

In Belgium, the first retrospective serological study was performed on archived samples from nursery pigs, fattening pigs, and young sows by IPMA, showing that the presence of PCV2 dates back to 1985 ([@vez026-B28]); another detailed serological survey of PCV2 antibodies in domestic and feral pig population later in Belgium showed the evidence of PCV2 infections in 1969 ([@vez026-B57]). Apart from these serological studies, little genetic information of PCV2 strains in Belgium was available. In the present study, we examined the molecular epidemiology and evolution of PCV2 strains circulating in Belgium, by evaluating the frequency of the virus detection, the genotype distribution, and their heterogeneity from archived diagnostic samples from 2009 till 2018. This study is the first report on the molecular characterization of Belgian PCV2 strains.

Despite the early presence of PCV2 in 1969, Belgian farms were rarely affected by PMWS-related problems. In three Belgian farms with a history of PMWS, the percentage of PMWS-positive piglets was very low (2%) compared to those described in the UK (up to 22%), USA (up to 15%), France (11%), and Spain (up to 30%) ([@vez026-B24]; [@vez026-B15]; [@vez026-B32]; [@vez026-B59]; [@vez026-B36]). Until now, only four Belgian PCV2 strains were isolated from PMWS-affected piglets. Strains 1206 and VC2002-K39 were identified as PCV2b, strain VC2002-K2 as PCV2d-1 and strain 4D4 as a recombinant strain of VC2002-K2 and VC2002-K39 ([@vez026-B29]). The successful application of vaccination, improved biosafety measures, and better hygiene may explain the decreased number of samples that were sent in our laboratory for PCV2 diagnosis from 2014 to 2018. Another reason could be that PCV2 diagnosis became a routine in a number of laboratories across Belgium during that period, resulting samples being sent to other laboratories.

In this study, three PCV2 genotypes (PCV2a, PCV2b, and PCV2d) were identified in Belgium. PCV2b was the predominant genotype from 2009 till 2013. The three isolates from 2018 belonged to genotype PCV2d. Samples from 2014 to 2017 were negative for virus isolation and thus were not submitted for further PCR analysis. Only three cases of PCV2a were detected exclusively in 2009 in our study in Belgium, while on a worldwide scale PCV2a was the most dominant genotype in pig population before 2003 ([@vez026-B72]). During the period of 2003--4, a global shift occurred from genotype 2a to 2b. This agrees with the predominance of PCV2b from 2009 till 2013 in Belgium. In 2018, PCV2d, especially PCV2d-2, was the only circulating subtype in Belgium in our study. The emergence and spread of PCV2d-2, which appears to be replacing PCV2b, has been suggested in several studies ([@vez026-B72]; [@vez026-B13]). PCV2d-1 was only found in 2009 (1/6) and 2010 (5/6) in Belgium. This is in line with the global trend in the identification of PCV2d-1 between 1999 and 2011 and confirms the proposal that PCV2d-1 is a possible ancestor of PCV2d-2 ([@vez026-B72]). The emergence of PCV2d-1 concurred with the spread of PCV2b, indicating that PCV2b and PCV2d bifurcated early and evolved independently in the pig population ([@vez026-B72]). These findings generally indicate a genotype shift from PCV2a to PCV2b and from PCV2d-1 to PCV2d-2. The limited timeframe of our study and the absence of PCV2 genetic data between 2014 and 2017, made it difficult to determine the exact genetic changes in Belgium during that period.

Selection pressure plays a critical role in evolutionary biology by shaping genetic variation. The high mutation rate of PCV2, which is closer to that of a single-stranded RNA virus, can enhance the frequency of selection, as well as the rapid emergence of novel PCV2 genotypes. In our study, we identified three codons (positions 59, 131, and 191) in the capsid protein of Belgian PCV2 under positive selection pressure. Positions 59 and 191 are crucial in neutralizing activities, while the position 131 is related to the growth ability of PCV2. Broad vaccination, which was used to control numerous PCVADs, might contribute to the alteration of antigenic properties. Research on the role of vaccination in PCV2 evolution is extremely challenging because of the difficulty in recruiting a large number of farms where vaccination has not been applied despite PCV2 circulation. However, it is interesting to note that the first genotype shift from PCV2a to PCV2b during the period of 2003--4 predates the vaccination against PCV2 using PCV2a-type commercial vaccines (first registration in 2007; Circovac^®^, Merial). This genotype shift/evolution is probably mainly driven by infection immunity which is present on all farms. Although the ongoing genotype shift from PCV2b to PCV2d occurs in the background of extensive vaccination with the PCV2a-type vaccines, PCV2 infections still occur and induce a strong population immunity. Vaccination did not reduce the variability of PCV2 strains in vaccinated herds ([@vez026-B46]). As a result, it is likely that population immunity against circulating wild-type PCV2 viruses is the main driving force behind the genotypic evolution.

Since the PCV2 capsid protein is immunogenic, mutations on the capsid protein may explain the direction of PCV2 genotypic evolution. Mapping genotype-specific amino acids on the 3D structure of the cap protein of different genotypes is of great interest. It helps to identify the real locations of amino acids on the cap protein, thus revealing the possible effect of amino acid mutations on the structure of the virion and on the interaction of virions with the environment (e.g. receptors). In the current study, the amino acids on the inner part of the cap protein (where the cap protein interacts with the viral genome) were conserved to maintain the stability of PCV virion, and most amino acid mutations were found on the surface of the cap protein (where the cap protein interacts with the environment). Mutations on the upper part of the cap protein consisted of more basic amino acid clusters and the lower part more conserved but somewhat less basic ([Fig. 2](#vez026-F2){ref-type="fig"}). The tail was extended with one amino acid and remained basic. It is likely that the capsid protein has mutated to escape from the host immunity, evolving to bind more strongly to its GAG receptors. This may explain the grouping of basic amino acids in an area composed of the 'head' of one capsomere and the 'tail' of the neighbouring capsomere and the longer extended basic 'tail' ([Fig. 3](#vez026-F3){ref-type="fig"}). It appears that PCV2d has formed an extruding part to the cap protein, which improves the efficiency of binding of the virus to the target cell.

![Hypothetical model on the evolutionary amino acid mutations on the 'head' and 'tail' of the cap protein. (A) Front side: Surface mapping of amino acid mutations on the head (positions 59, 206, and 63) and tail (positions 232 and 234) of the cap protein across three genotypes. (B) Three subunits forming a trimer, with indications of the changes mentioned in (A). For PCV2a-Fh17 and PCV2b-1206, the head of one capsomere is close to the tail of the neighbouring capsomere; while for PCV2d-K2, the head of one capsomere is apart from the tail of the neighbouring capsomere, and both the head and tail extrude further from the capsid surface. The trimer was generated by SYMMDOCK server ([@vez026-B58]). The 3D structures of capsid were generated using I-TASSER server and displayed with PyMOL.](vez026f3){#vez026-F3}

Comparison of the complete ORF2 sequences of forty-three Belgian PCV2 isolates revealed 89.7--100 per cent nucleotide homology and 88.5--100 per cent amino acid sequence identity. Amino acid comparisons showed that a greater diversity was found in the regions 53--91, 121--136, and 169--217 and at the positions 151, 232, and 234. Similar non-conserved regions have been demonstrated in another report ([@vez026-B69]). These regions contain immunorelevant epitopes (residues 65--87, 113--139, and 193--207) identified using pepscan analysis ([@vez026-B35]). Frequent mutations in these regions may change the antigenic features of PCV2 and help the virus to evade the immune response, thus promoting virus propagation under field conditions. Specifically, position 59 is a critical amino acid that is part of the neutralizing epitope ([@vez026-B20]); positions 131 and 190 are important for determining neutralization activity ([@vez026-B52]); region 163--180 is suggested as a decoy epitope resulting in the production of non-neutralizing antibodies against PCV2 ([@vez026-B65], [@vez026-B66]). Position 233 is critical in maintaining effective binding between the epitope and antibody, which is conserved among all genotypes in our study ([@vez026-B62]). Interestingly, a pair of signature motifs in the ORF2 (aa position 86--91) of PCV2 which was described to distinguish viruses of genotype 2a (peptide sequence 86TNKISI91) from strains of genotype 2b (86SNPRSV91), can also distinguish viruses of genotype 2d (86SNPLTV91) in our study ([@vez026-B5]; [@vez026-B69]). Thus, amino acids in region 86--91 can serve as a 'genetic marker' to distinguish these three genotypes.

In this study, only the tissue samples from which virus was isolated were subjected to further PCR analysis (except for the serum samples in 2018). We believe that virus isolation is the 'gold standard' method to demonstrate that PCV2 is related to disease, based on the fact that DNA of circoviruses is detected everywhere nowadays and that this DNA is not always associated with viable virus. For instance, the contaminating PCV, which was detected in a porcine-derived commercial pepsin product by PCR, was confirmed to be non-infectious as demonstrated by both *in vitro* and *in vivo* infection experiments ([@vez026-B11]). The PCV DNA detected in some rotavirus vaccines by qPCR consisted of small fragments of PCV genetic material since the full length or partial amplicons of PCV could not be amplified by conventional PCR ([@vez026-B9]). PCV2 DNA was detected in water samples in Brazil, farm air in Canada, house flies in UK ([@vez026-B67]; [@vez026-B3]; [@vez026-B14]). Even in soil, PCV2 genome components were demonstrated ([@vez026-B23]). In the USA, 70 per cent of the store-bought pork products contain PCV sequences. This resulted in the detection of PCV in stool samples from adults in the USA (5%) possibly due to the dietary consumption of PCV-infected pork ([@vez026-B31]). Interestingly, previous work from our laboratory demonstrated that monocytic cells, known as scavenger cells and being responsible for cleaning up foreign material in the body, can indeed take up PCV2 virions and disintegrate viral capsids, but have problems with degrading/digesting PCV2 DNA ([@vez026-B70]). The difficult-to-degrade property of PCV2 genome may explain the ubiquitous presence of the viral DNA. Taken together, it is clear that the detection of PCV2 genetic material does not automatically mean that the sample contains complete, viable, and infectious PCV2 virions. This important yet overlooked information alerts us on the use of the PCR, especially the sensitive qPCR for diagnostic purposes. Normally the advisable product length of qPCR is around 150--200 bp, which means only a small part of the viral genome is amplified. Can one state that pigs are positive for PCV2 based on the detection of such small fragments of the PCV2 genome? As to the question of whether pigs should be considered as positive for PCV2 based on the detection of such small fragments of the PCV2 genome, we feel that virus should be successfully isolated, or at least the full length of PCV2 genome amplified by conventional PCR, together with observations of PCVAD clinical and pathological manifestations from pigs, before PCV2 should be considered as contributing to the clinical disease observed.

In conclusion, we demonstrated that at least three genotypes (PCV2a, PCV2b, and PCV2d) circulated in Belgium from 2009 till 2018, and that PCV2 evolved from PCV2a to PCV2b and from PCV2d-1 to PCV2d-2. Mapping PCV2 genotype-specific amino acids on the 3D structure of the capsid protein revealed that most of the mutations were on the outside of the cap protein, with a few conserved mutations on the inner side of the protein. Mutations on the upper and tail parts of the capsid protein evolved toward a more efficient binding to GAGs, while the lower part of the protein was relatively conserved. Additional epidemiological studies, including a retrospective analysis of virus circulation in Belgium before 2009, along with more continuous up-to-date surveillance, are needed to better understand the epidemic and evolutionary dynamics of PCV2 in Belgium, and to see how the situation in Belgium conforms to what is known about the global evolution of PCV2.

Authors' contributions
======================

R.W. and H.J.N. conceived and designed the experiments; R.W. performed the experiments; R.W., J.X., and S.T. analyzed the data; R.W. wrote the article and H.J.N. revised the article.

Supplementary Material
======================

###### 

Click here for additional data file.

The authors thank Carine Boone for her excellent technical assistance.

Funding
=======

R.W. was supported by the China Scholarship Council (201406300044). This research received no scientific funding.

**Conflict of interest:** The authors declare no conflict of interest.
